Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Life Sci ; 333: 122132, 2023 Nov 15.
Article in English | MEDLINE | ID: mdl-37793482

ABSTRACT

A diverse and stable microbiota promotes a healthy state, nevertheless, an imbalance in gut or oral bacterial composition, called dysbiosis, can cause gastrointestinal disorders, systemic inflammatory states and oxidative stress, among others. Recently, gut and oral dysbiosis has been linked to Alzheimer's disease (AD), which is considered the most common form of dementia and a public health priority due to its high prevalence and incidence. The aim of this review is to highlight the implications of gut and oral microbiota in the neuroinflammation characteristic of AD pathology and the subsequent cognitive impairment. It is a systematic review of the current literature obtained by searching the PubMed, Web of Science and Scopus databases. The characteristic intestinal dysbiosis in AD patients leads to increased permeability of the intestinal barrier and activates immune cells in the central nervous system due to translocation of microbiota-derived metabolites and/or bacteria into the circulation leading to increased neuroinflammation and neuronal loss, thus generating the cognitive impairment characteristic of AD. The presence in the central nervous system of Porphyromonas gingivalis can cause an increased neuroinflammation and beta-amyloid peptide accumulation.


Subject(s)
Alzheimer Disease , Gastrointestinal Microbiome , Microbiota , Humans , Alzheimer Disease/metabolism , Gastrointestinal Microbiome/physiology , Neuroinflammatory Diseases , Dysbiosis/complications , Dysbiosis/metabolism , Inflammation/pathology , Bacteria , Brain/metabolism
2.
Front Med (Lausanne) ; 10: 1204151, 2023.
Article in English | MEDLINE | ID: mdl-37575999

ABSTRACT

Background: The lockdown imposed during the COVID-19 pandemic led to social isolation and prevented patients with dementia from receiving a suite of non-pharmacological interventions (NPIs) that prevent cognitive decline. This discontinuation of NPIs could substantially affect the mental health status of people with dementia in social care settings, such as adult day care centers (ADCs). Propose: The study aimed to evaluate the effects of the COVID-19 lockdown on mental health and cognitive impairment in patients with dementia who could not attend their usual ADCs and did not receive our NPIs, based on World Health Organization (WHO) Guidelines. Methods: Observational, longitudinal, retrospective study carried out in an adult day center in Spain and reported it in accordance with the Strengthening Reporting of Observational Studies in Epidemiology (STROBE) statement. Cognitive status was assessed using the Mini-Mental State Examination (MMSE) in 80 patients attending the ADC of the "Leonese Association of Dementia Patients" (León, Spain), who had been evaluated with this instrument before the COVID-19 lockdown. Results: We observed a 0.4-point decrease in MMSE score/month (IQR = 1.4) during lockdown versus a 0.1-point decrease/month (IQR = 0.3) before this period (p = 0.038). Notably, this translated to >10-point decreases in MMSE score/year in 33.8% of participants during lockdown versus 5.5% earlier (p < 0.001). No statistically significant associations (p < 0.05) were found between the individual characteristics of the caregivers and the occurrence of the event. Conclusion: The reported declines in MMSE scores reveal a significant acceleration of cognitive decline during the period of inactivity. This could suggest that our NPIs, focused on slowing cognitive decline, are beneficial and, therefore, necessary in patients with dementia.

3.
Front Pharmacol ; 14: 1185602, 2023.
Article in English | MEDLINE | ID: mdl-37448966

ABSTRACT

Suppressive antibiotic therapy (SAT) is a strategy to alleviate symptoms and/or to reduce the progression of an infection when other treatment options cannot be used. Dalbavancin, due to its prolonged half-life, enables (bi) weekly dosing. Here, we report our multicenter real-life clinical experience with dalbavancin used as SAT in patients with prosthetic joint or vascular infections. Medical records of all adult patients with documented vascular or orthopedic chronic prosthetic infections, who received dalbavancin as SAT between 2016 and 2018 from four Spanish hospitals were reviewed for inclusion. Descriptive analysis of demographic characteristics, Charlson Comorbidity index, Barthel index, isolated pathogens and indication, concomitant antibiotic use, adverse events, and clinical outcome of SAT were performed. Eight patients were eligible for inclusion, where six patients had prosthetic vascular infections (aortic valve) and two patients had knee prosthetic joint infections. The most common pathogens were methicillin-susceptible Staphylococcus aureus and Enterococcus faecium. All patients had a history of prior antibiotic treatment for the prosthetic infection [median duration of antibiotic days 125 days (IQR, 28-203 days)]. The median number of dalbavancin doses was 29 (IQR, 9-61) and concomitant antibiotic use (n = 5, 62.5%). Clinical success was reported in 75% (n = 6) of patients. Adverse events were reported in two patients (mild renal and hepatic impairment). The median estimated cost savings due to the avoided hospital days was €60185 (IQR, 19,916-94984) per patient. Despite the limitations of our study, this preliminary data provides valuable insight to support further evaluation of dalbavancin for SAT in patients with prosthetic infections in the outpatient setting when alternative treatments are not feasible.

4.
Rev. Rol enferm ; 46(5): 298-302, may. 2023. ilus
Article in Spanish | IBECS | ID: ibc-220389

ABSTRACT

La evaluación de la actividad de los investigadores, de sus publicaciones y de las revistas donde se publican dichos trabajos, es un proceso continuo y necesario para poder valorar la calidad y el impacto de los mismos. Estas revistas están indexadas en diferentes bases de datos, siendo la Web Of Science una de las más importantes, junto con Scopus, debido a la cantidad de información que tiene recogida y a los rigurosos criterios que deben cumplir las revistas para ser incluidas en ella. Una nueva herramienta de esta base de datos es el Emerging Sources Citation Index, que contiene revistas que o bien están en proceso de evaluación, o bien son revistas que presentan una calidad científica acreditada en su disciplina, pero que nunca llegarán a integrarse en la Web of Science ya que su área de conocimiento es limitada y previsiblemente nunca llegaran a tener un factor de impacto suficientemente alto. El estar incluido en este recurso, como lo está ROL Revista de Enfermería, tiene un gran valor para las revistas y para los autores que publican sus trabajos en ellas ya que supone un mérito valorado en la mayoría de los procesos de evaluación de los investigadores, como por ejemplo en la Agencia Nacional de Evaluación de la Calidad y Acreditación (ANECA). (AU)


The evaluation of the activity of researchers, their publications and the journals where these works are published, is a continuous and necessary process to assess their quality and impact. These journals are indexed in different databases, being Web Of Science one of the most important, together with Scopus, due to the amount of information it has collected and the rigorous criteria that journals must meet to be included in it. A new tool of this database is the Emerging Sources Citation Index, which contains journals that are either in the process of evaluation, or are journals that have a proven scientific quality in their discipline, but that will never be included in the Web of Science because their area of knowledge is limited and they will probably never have a sufficiently high impact factor. Being included in this resource, as ROL Revista de Enfermería is, has a great value for the journals and for the authors who publish their work in them, since it is a merit valued in most of the evaluation processes of researchers, such as the National Agency for Quality Assessment and Accreditation (ANECA). (AU)


Subject(s)
Humans , Journal Impact Factor , Nursing Research , Biomedical Research , Spain , Databases, Bibliographic , Authorship in Scientific Publications
5.
Nutrients ; 15(2)2023 Jan 11.
Article in English | MEDLINE | ID: mdl-36678248

ABSTRACT

The aim of this study was to analyze the possible nephroprotective effect of 3',4'-dihydroxyphenylglycol (DHPG), a polyphenolic compound of extra virgin olive oil (EVOO), on renal lesions in an experimental model of type 1 diabetes. Rats were distributed as follows: healthy normoglycemic rats (NDR), diabetic rats treated with saline (DR), and DR treated with 0.5 mg/kg/day or 1 mg/kg/day of DHPG. DR showed a significantly higher serum and renal oxidative and nitrosative stress profile than NDR, as well as reduced prostacyclin production and renal damage (defined as urinary protein excretion, reduced creatinine clearance, increased glomerular volume, and increased glomerulosclerosis index). DHPG reduced the oxidative and nitrosative stress and increased prostacyclin production (a 59.2% reduction in DR and 34.7-7.8% reduction in DHPG-treated rats), as well as 38-56% reduction in urinary protein excretion and 22-46% reduction in glomerular morphological parameters (after the treatment with 0.5 or 1 mg/kg/day, respectively). Conclusions: DHPG administration to type 1-like diabetic rats exerts a nephroprotective effect probably due to the sum of its antioxidant (Pearson's coefficient 0.68-0.74), antinitrosative (Pearson's coefficient 0.83), and prostacyclin production regulator (Pearson's coefficient 0.75) effects.


Subject(s)
Diabetes Mellitus, Experimental , Diabetic Nephropathies , Rats , Animals , Olive Oil/pharmacology , Diabetic Nephropathies/drug therapy , Diabetes Mellitus, Experimental/metabolism , Phenols/pharmacology , Prostaglandins I/metabolism , Prostaglandins I/pharmacology , Oxidative Stress
7.
Healthcare (Basel) ; 10(5)2022 Apr 20.
Article in English | MEDLINE | ID: mdl-35627899

ABSTRACT

The objective was to quantify oxidative stress resulting from ischemia during the donation process, using malondialdehyde (MDA) measurement, and its modulation by the administration of melatonin. We designed a triple-blind clinical trial with donors randomized to melatonin or placebo. We collected donors by donation after brain death (DBD) and controlled donation after circulatory death (DCD), the latter maintained by normothermic regional perfusion (NRP). Melatonin or placebo was administered prior to donation or following limitation of therapeutic effort (LTE). Demographic variables and medical history were collected. We also collected serial measurements of MDA, at 60 and 90 min after melatonin or placebo administration. A total of 53 donors were included (32 from DBD and 21 from DCD). In the DBD group, 17 donors received melatonin, and 15 placebo. Eight DCD donors were randomized to melatonin and 13 to placebo. Medical history and cause for LTE were similar between groups. Although MDA values did not differ in the DBD group, statistical differences were observed in DCD donors during the 0-60 min interval: -4.296 (-6.752; -2.336) in the melatonin group and -1.612 (-2.886; -0.7445) in controls. Given the antioxidant effect of melatonin, its use could reduce the production of oxidative stress in controlled DCD.

8.
J Antimicrob Chemother ; 77(5): 1452-1460, 2022 04 27.
Article in English | MEDLINE | ID: mdl-35187577

ABSTRACT

BACKGROUND: Infections caused by carbapenemase-producing Enterobacterales (CPE) are not well represented in pivotal trials with ceftazidime/avibactam. The best strategy for the treatment of these infections is unknown. METHODS: We conducted a multicentre retrospective observational study of patients who received ≥48 h of ceftazidime/avibactam or best available therapy (BAT) for documented CPE infections. The primary outcome was 30 day crude mortality. Secondary outcomes were 21 day clinical response and microbiological response. A multivariate logistic regression model was used to identify factors predictive of 30 day crude mortality. A propensity score to receive treatment with ceftazidime/avibactam was used as a covariate in the analysis. RESULTS: The cohort included 339 patients with CPE infections. Ceftazidime/avibactam treatment was used in 189 (55.8%) patients and 150 (44.2%) received BAT at a median of 2 days after diagnosis of infection. In multivariate analysis, ceftazidime/avibactam treatment was associated with survival (OR 0.41, 95% CI 0.20-0.80; P = 0.01), whereas INCREMENT-CPE scores of >7 points (OR 2.57, 95% CI 1.18-1.5.58; P = 0.01) and SOFA score (OR 1.20, 95% CI 1.08-1.34; P = 0.001) were associated with higher mortality. In patients with INCREMENT-CPE scores of >7 points, ceftazidime/avibactam treatment was associated with lower mortality compared with BAT (16/73, 21.9% versus 23/49, 46.9%; P = 0.004). Ceftazidime/avibactam was also an independent factor of 21 day clinical response (OR 2.43, 95% CI 1.16-5.12; P = 0.02) and microbiological eradication (OR 0.40, 95% CI 0.18-0.85; P = 0.02). CONCLUSIONS: Ceftazidime/avibactam is an effective alternative for the treatment of CPE infections, especially in patients with INCREMENT-CPE scores of >7 points. A randomized controlled trial should confirm these findings.


Subject(s)
Anti-Bacterial Agents , Ceftazidime , Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Bacterial Proteins , Ceftazidime/therapeutic use , Drug Combinations , Humans , Microbial Sensitivity Tests , beta-Lactamases
9.
Front Neurosci ; 15: 677777, 2021.
Article in English | MEDLINE | ID: mdl-34489620

ABSTRACT

Alzheimer's disease (AD) is a primary, progressive, neurodegenerative disorder. Many risk factors for the development of AD have been investigated, including nutrition. Although it has been proven that nutrition plays a role in AD, the precise mechanisms through which nutrition exerts its influence remain undefined. The object of this study is to address this issue by elucidating some of the mechanisms through which nutrition interacts with AD. This work is a qualitative systematic bibliographic review of the current literature searchable on various available databases, including PubMed, Web of Science, and Google Scholar. Our evidence comprises 31 articles selected after a systematic search process. Patients suffering with AD present a characteristic microbiome that promotes changes in microglia generating a proinflammatory state. Many similarities exist between AD and prion diseases, both in terms of symptoms and in the molecular mechanisms of pathogenesis. Changes in the composition of the gut microbiome due to dietary habits could be one of the environmental factors affecting the development of AD; however, this is probably not the only factor. Similarly, the mechanism for self-propagation of beta-amyloid seen in AD is similar to that seen in prions.

11.
Eur J Intern Med ; 64: 63-71, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30904433

ABSTRACT

PURPOSE: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. METHODS: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. RESULTS: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32-3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39-1.88),and non-performed surgery (HR:1.64;95% CI:11.16-1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. CONCLUSION: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group.


Subject(s)
Age Factors , Comorbidity , Endocarditis/mortality , Adult , Aged , Aged, 80 and over , Area Under Curve , Databases, Factual , Endocarditis/etiology , Female , Heart Failure/mortality , Hospital Mortality , Humans , Male , Middle Aged , Proportional Hazards Models , Prospective Studies , ROC Curve , Risk Factors , Spain/epidemiology , Staphylococcal Infections/mortality
12.
Am J Physiol Heart Circ Physiol ; 315(3): H563-H570, 2018 09 01.
Article in English | MEDLINE | ID: mdl-29949382

ABSTRACT

Cardiac fibroblasts are critical mediators of fibrotic remodeling in the failing heart and transform into myofibroblasts in the presence of profibrotic factors such as transforming growth factor-ß. Myocardial fibrosis worsens cardiac function, accelerating the progression to decompensated heart failure (HF). We investigated the effects of a novel inhibitor (NM922; NovoMedix, San Diego, CA) of the conversion of normal fibroblasts to the myofibroblast phenotype in the setting of pressure overload-induced HF. NM922 inhibited fibroblast-to-myofibroblast transformation in vitro via a reduction of activation of the focal adhesion kinase-Akt-p70S6 kinase and STAT3/4E-binding protein 1 pathways as well as via induction of cyclooxygenase-2. NM922 preserved left ventricular ejection fraction ( P < 0.05 vs. vehicle) and significantly attenuated transverse aortic constriction-induced LV dilation and hypertrophy ( P < 0.05 compared with vehicle). NM922 significantly ( P < 0.05) inhibited fibroblast activation, as evidenced by reduced myofibroblast counts per square millimeter of tissue area. Picrosirius red staining demonstrated that NM922 reduced ( P < 0.05) interstitial fibrosis compared with mice that received vehicle. Similarly, NM922 hearts had lower mRNA levels ( P < 0.05) of collagen types I and III, lysyl oxidase, and TNF-α at 16 wk after transverse aortic constriction. Treatment with NM922 after the onset of cardiac hypertrophy and HF resulted in attenuated myocardial collagen formation and adverse remodeling with preservation of left ventricular ejection fraction. Future studies are aimed at further elucidation of the molecular and cellular mechanisms by which this novel antifibrotic agent protects the failing heart. NEW & NOTEWORTHY Our data demonstrated that a novel antifibrotic agent, NM922, blocks the activation of fibroblasts, reduces the formation of cardiac fibrosis, and preserves cardiac function in a murine model of heart failure with reduced ejection fraction.


Subject(s)
Cardiotonic Agents/pharmacology , Heart Failure/drug therapy , Myofibroblasts/drug effects , Sulfonamides/pharmacology , Ventricular Remodeling/drug effects , Animals , Cardiotonic Agents/therapeutic use , Cells, Cultured , Collagen/metabolism , Humans , Male , Mice , Mice, Inbred C57BL , Myofibroblasts/metabolism , Protein-Lysine 6-Oxidase/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , STAT3 Transcription Factor/metabolism , Sulfonamides/chemistry , Sulfonamides/therapeutic use , Transforming Growth Factor beta/metabolism
15.
Hum Mol Genet ; 24(5): 1400-9, 2015 Mar 01.
Article in English | MEDLINE | ID: mdl-25355421

ABSTRACT

SMARCA4 is the catalytic subunit of the SWI/SNF chromatin-remodeling complex, which alters the interactions between DNA and histones and modifies the availability of the DNA for transcription. The latest deep sequencing of tumor genomes has reinforced the important and ubiquitous tumor suppressor role of the SWI/SNF complex in cancer. However, although SWI/SNF complex plays a key role in gene expression, the regulation of this complex itself is poorly understood. Significantly, an understanding of the regulation of SMARCA4 expression has gained in importance due to recent proposals incorporating it in therapeutic strategies that use synthetic lethal interactions between SMARCA4-MAX and SMARCA4-SMARCA2. In this report, we found that the loss of expression of SMARCA4 observed in some primary lung tumors, whose mechanism was largely unknown, can be explained, at least partially by the activity of microRNAs (miRNAs). We reveal that SMARCA4 expression is regulated by miR-101, miR-199 and especially miR-155 through their binding to two alternative 3'UTRs. Importantly, our experiments suggest that the oncogenic properties of miR-155 in lung cancer can be largely explained by its role inhibiting SMARCA4. This new discovered functional relationship could explain the poor prognosis displayed by patients that independently have high miR-155 and low SMARCA4 expression levels. In addition, these results could lead to application of incipient miRNA technology to the aforementioned synthetic lethal therapeutic strategies.


Subject(s)
DNA Helicases/metabolism , Gene Expression Regulation, Neoplastic , Lung Neoplasms/diagnosis , Lung Neoplasms/genetics , MicroRNAs/metabolism , Nuclear Proteins/metabolism , Transcription Factors/metabolism , Catalytic Domain , Cell Line, Tumor , Cell Nucleus/genetics , Cell Proliferation , Chromatin Assembly and Disassembly , Cloning, Molecular , DNA Helicases/genetics , HeLa Cells , High-Throughput Nucleotide Sequencing , Histones , Humans , MicroRNAs/genetics , Nuclear Proteins/genetics , Prognosis , Reproducibility of Results , Transcription Factors/genetics , Up-Regulation
16.
Nat Struct Mol Biol ; 21(9): 803-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25108355

ABSTRACT

The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide, therapeutically important drugs for multiple myeloma and other B-cell malignancies. These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degradation. Here we present the crystal structure of human CRBN bound to DDB1 and the drug lenalidomide. A hydrophobic pocket in the thalidomide-binding domain (TBD) of CRBN accommodates the glutarimide moiety of lenalidomide, whereas the isoindolinone ring is exposed to solvent. We also solved the structures of the mouse TBD in the apo state and with thalidomide or pomalidomide. Site-directed mutagenesis in lentiviral-expression myeloma models showed that key drug-binding residues are critical for antiproliferative effects.


Subject(s)
Angiogenesis Inhibitors/pharmacology , DNA-Binding Proteins/metabolism , Peptide Hydrolases/metabolism , Thalidomide/analogs & derivatives , Adaptor Proteins, Signal Transducing , Amino Acid Sequence , Angiogenesis Inhibitors/chemistry , Animals , Crystallography, X-Ray , DNA-Binding Proteins/chemistry , Humans , Lenalidomide , Mice , Molecular Docking Simulation , Molecular Sequence Data , Peptide Hydrolases/chemistry , Protein Binding , Protein Conformation , Protein Structure, Tertiary , Sequence Alignment , Thalidomide/chemistry , Thalidomide/pharmacology , Ubiquitin-Protein Ligases
17.
Blood ; 124(10): 1637-44, 2014 Sep 04.
Article in English | MEDLINE | ID: mdl-24990888

ABSTRACT

Lenalidomide has demonstrated clinical activity in patients with chronic lymphocytic leukemia (CLL), even though it is not cytotoxic for primary CLL cells in vitro. We examined the direct effect of lenalidomide on CLL-cell proliferation induced by CD154-expressing accessory cells in media containing interleukin-4 and -10. Treatment with lenalidomide significantly inhibited CLL-cell proliferation, an effect that was associated with the p53-independent upregulation of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) (p21). Silencing p21 with small interfering RNA impaired the capacity of lenalidomide to inhibit CLL-cell proliferation. Silencing cereblon, a known molecular target of lenalidomide, impaired the capacity of lenalidomide to induce expression of p21, inhibit CD154-induced CLL-cell proliferation, or enhance the degradation of Ikaros family zinc finger proteins 1 and 3. We isolated CLL cells from the blood of patients before and after short-term treatment with low-dose lenalidomide (5 mg per day) and found the leukemia cells were also induced to express p21 in vivo. These results indicate that lenalidomide can directly inhibit proliferation of CLL cells in a cereblon/p21-dependent but p53-independent manner, at concentrations achievable in vivo, potentially contributing to the capacity of this drug to inhibit disease-progression in patients with CLL.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Cell Proliferation/drug effects , Cyclin-Dependent Kinase Inhibitor p21/physiology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Peptide Hydrolases/physiology , Thalidomide/analogs & derivatives , Adaptor Proteins, Signal Transducing , Gene Expression Regulation, Leukemic/drug effects , HeLa Cells , Humans , Lenalidomide , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Signal Transduction/drug effects , Thalidomide/pharmacology , Tumor Cells, Cultured , Tumor Suppressor Protein p53/physiology , Ubiquitin-Protein Ligases
18.
J Antimicrob Chemother ; 68(8): 1917-25, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23557925

ABSTRACT

BACKGROUND: Conflicting evidence has been reported on the impact of ertapenem use on the susceptibility of Pseudomonas spp. to group 2 carbapenems. No extensive data for Acinetobacter baumannii are currently available. METHODS: A retrospective time-series segmented regression analysis was conducted in a tertiary centre from January 2001 to December 2011. Ertapenem was introduced in January 2005. Antimicrobial drug use was defined as the number of defined daily doses/100 patient-days (DDDs/100 PDs). Susceptibility (CLSI) was measured in terms of proportion and incidence density. RESULTS: Mean monthly use of imipenem was 2.9 ±â€Š0.9 DDDs/100 PDs, as compared with 1.2 ±â€Š0.7 DDDs/100 PDs for meropenem and 1.0 ±â€Š0.7 DDDs/100 PDs for ertapenem (after its introduction). After ertapenem adoption, a downward trend was seen in the use of imipenem (P = 0.016) and ciprofloxacin (P = 0.004). A total of 6272 Pseudomonas aeruginosa and 1093 A. baumannii isolates were evaluated. Susceptibility of P. aeruginosa to imipenem improved after ertapenem introduction, both according to the proportion of susceptible isolates (P = 0.002) and to the incidence density of resistance (P ≤ 0.001). No significant change was seen in A. baumannii susceptibility to imipenem (P = 0.772). By multiple linear regression analysis, the incidence density of imipenem-resistant P. aeruginosa increased with the use of imipenem (P = 0.003) and ciprofloxacin (P = 0.008). Occurrence of outbreaks (P ≤ 0.001) and use of gentamicin (P = 0.007) were associated with A. baumannii resistance to imipenem. CONCLUSIONS: Use of ertapenem was directly associated with a downward trend in the use of imipenem and ciprofloxacin, which may have contributed to improve the susceptibility of P. aeruginosa to imipenem. Ertapenem use had no impact on the susceptibility of A. baumannii to imipenem.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Imipenem/pharmacology , Pseudomonas aeruginosa/drug effects , beta-Lactam Resistance , beta-Lactams/therapeutic use , Acinetobacter baumannii/isolation & purification , Ciprofloxacin/therapeutic use , Cross Infection/drug therapy , Cross Infection/microbiology , Drug Utilization/statistics & numerical data , Ecosystem , Ertapenem , Humans , Microbial Sensitivity Tests , Pseudomonas aeruginosa/isolation & purification , Retrospective Studies , Selection, Genetic , Tertiary Care Centers
19.
Bioorg Med Chem Lett ; 23(1): 360-5, 2013 Jan 01.
Article in English | MEDLINE | ID: mdl-23168019

ABSTRACT

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.


Subject(s)
Thalidomide/analogs & derivatives , Administration, Oral , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Half-Life , Humans , Interleukin-2/metabolism , Lenalidomide , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Rats , Structure-Activity Relationship , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Thalidomide/chemistry , Thalidomide/pharmacokinetics , Thalidomide/toxicity , Tumor Necrosis Factor-alpha/metabolism
20.
Blood ; 118(4): 1109-12, 2011 Jul 28.
Article in English | MEDLINE | ID: mdl-21536862

ABSTRACT

Pharmacologic induction of fetal hemoglobin (HbF) expression is an effective treatment strategy for sickle cell disease (SCD) and ß-thalassemia. Pomalidomide is a potent structural analog of thalidomide and member of a new class of immunomodulatory drugs. Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requirements in certain hematologic malignancies and induced HbF ex vivo in CD34(+) progenitor cells from healthy and SCD donors. We investigated the effects of pomalidomide on erythropoiesis and hemoglobin synthesis in a transgenic mouse model of SCD. We found that 8 weeks of treatment with pomalidomide induced modest increases of HbF with similar efficacy as hydroxyurea. However, in stark contrast to hydroxyurea's myelosuppressive effects, pomalidomide augmented erythropoiesis and preserved bone marrow function. Surprisingly, combinatory therapy with both drugs failed to mitigate hydroxyurea's myelotoxic effects and caused loss of HbF induction. These findings support further evaluation of pomalidomide as a novel therapy for SCD.


Subject(s)
Anemia, Sickle Cell/blood , Antisickling Agents/pharmacology , Bone Marrow/drug effects , Erythropoiesis/drug effects , Fetal Hemoglobin/drug effects , Thalidomide/analogs & derivatives , Animals , Disease Models, Animal , Hydroxyurea/adverse effects , Mice , Mice, Knockout , Mice, Transgenic , Thalidomide/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...